Amgen Inc.

Agouron Pharmaceuticals, Inc.

Amgen Fremont Inc.

Junming Yie

Ian Nevin Foltz

Murielle M Veniant-Ellison

Zhulun Wang

Neeraj Jagdish Agrawal

Xiaoshan Min

Darren L Bates

Donghui Shi

Christopher Murawsky

David J Lloyd

Jinghong Wang

Shu-yin Ho

Brandon C P Clavette

Renee Komorowski

Glenn N Sivits, Jr

Yang Li

Chadwick Terence King

Bin Wu

Gunasekaran Kannan

Yuan Cheng

Shaw-Fen Sylvia Hu

Leslie Phillip Miranda

James Richard Falsey

Bradley J Herberich

Jerry Ryan Holder

Jennitte LeAnn Stevens

Shu-Chen Lu

Chawita Netirojjanakul

Shanaka Stanislaus

Larry L Green

Jing M Xu

Kelvin C Sham

Jing Xu

Eva Rose Chin

Chikwendu Ibebunjo

Philip Albert Krasney

Joseph Zachweija

Kelvin Sham

Murielle M Venient-Ellison

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR)

Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)

The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing &#x3b2;-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising &#x3b2;-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c.

Antigen binding proteins that bind to a complex comprising &#x3b2;-Klotho and an FGF receptor

Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists

The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling.

Human antigen binding proteins that bind to a complex comprising &#x3b2;-Klotho and an FGF receptor

The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to myostatin, and that function to inhibit myostatin. The invention also relates to human anti-myostatin antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-myostatin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-myostatin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-myostatin antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

Antibodies to myostatin

Growing community of inventors

Warren, NJ, United States of America

Junming Yie